The complaint, filed by the law firm Bronstein, Gewirtz & Grossman, LLC, alleges that the biotechnology firm failed to disclose significant vulnerabilities that left its ordinary shares exposed to extreme volatility. According to the filing, these omissions subjected shareholders to heightened regulatory risks and eventual financial harm. The lawsuit argues that the company's public statements during the specified period were materially false, masking systemic weaknesses in compliance and operations.

Investors who purchased Regencell securities during the class period have until June 23, 2026, to apply for lead plaintiff status. While the firm operates on a contingency fee basis—meaning legal costs are only recovered if the litigation succeeds—individual shareholders can participate in potential settlements without taking on the role of lead plaintiff. Peretz Bronstein, founding partner of the firm, stated that the action aims to restore investor capital and enforce corporate accountability within the marketplace.